Patents by Inventor Juanita A. Johnson
Juanita A. Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7963935Abstract: The device including a plurality of stratum corneum-piercing microprojections, and a solid coating disposed upon the microprojections, wherein the solid coating includes at least one beneficial agent and a biocompatible carrier is provided. The device is applied to the skin of a living animal (e.g., a human), causing the microprojections to pierce the stratum corneum and deliver an effective dose of the agent to the animal.Type: GrantFiled: April 20, 2002Date of Patent: June 21, 2011Assignee: Alza CorporationInventors: Michel J. N. Cormier, Wendy A. Young, Juanita A. Johnson, Peter E. Daddona
-
Publication number: 20090186147Abstract: Methods are provided for preparation of a coating on one or more microprojections of a microprojection array using wetting agents either as a pretreatment of the microprojection surfaces or incorporated in the coating formulation along with the active agent.Type: ApplicationFiled: October 31, 2008Publication date: July 23, 2009Applicant: Alza CorporationInventors: Michel J.N. Cormier, Wendy A. Young, Juanita A. Johnson, Peter E. Daddona, Mahmoud Armeri
-
Publication number: 20090143724Abstract: Skin patches (20) having a microprojection array (10), a reservoir (18) containing an antigenic agent and an immune response augmenting adjuvant, and methods of using same to vaccinate animals (e.g., humans) is disclosed. In a preferred embodiment, the microprojection arrays (10) are composed of a photoetched and micro-punched titanium foil (14). The microprojections (12) are coated with a liquid formulation containing a vaccine antigen and an adjuvant such as glucosaminyl muramyl dipeptide, dried, and applied to skin of the animal to be vaccinated using an impact applicator. The microprojections (12) create superficial pathways through the stratum corneum to facilitate permeation of antigenic agent and adjuvant. Antigen dose and depth of penetration can be controlled. This technology has broad applicability for a wide variety of therapeutic vaccines to improve efficacy, and convenience of use.Type: ApplicationFiled: February 6, 2009Publication date: June 4, 2009Applicant: Alza CorporationInventors: Michel J.N. Cormier, James A. Matriano, Peter E. Daddona, Juanita A. Johnson, Wendy A. Young
-
Patent number: 7438926Abstract: This invention relates to a method for inhibiting a decrease in the transdermal flux of an agent that is being transdermally delivered or sampled over a prolonged period of time wherein the delivery or sampling involves disrupting at least the stratum corneum layer of the skin to form pathways through which the agent passes. The desired result is achieved by co-delivering or co-sampling the agent with an amount of at least one anti-healing agent wherein the amount of the anti-healing agent is effective in inhibiting a decrease in the agent transdermal flux compared to when the delivery or sampling of the agent is done under substantially identical conditions except in the absence of the anti-healing agent(s).Type: GrantFiled: September 8, 2001Date of Patent: October 21, 2008Assignee: Alza CorporationInventors: Michel Cormier, Juanita Johnson, Wei Qi Lin, James Matriano, Peter Daddona
-
Publication number: 20060074377Abstract: Skin patches (20) having a microprojection array (10), a reservoir (18) containing an antigenic agent and an immune response augmenting adjuvant, and methods of using same to vaccinate animals (e.g., humans) is disclosed. In a preferred embodiment, the microprojection arrays (10) are composed of a photoetched and micro-punched titanium foil (14). The microprojections (12) are coated with a liquid formulation containing a vaccine antigen and an adjuvant such as glucosaminyl muramyl dipeptide, dried, and applied to skin of the animal to be vaccinated using an impact applicator. The microprojections (12) create superficial pathways through the stratum corneum to facilitate permeation of antigenic agent and adjuvant. Antigen dose and depth of penetration can be controlled. This technology has broad applicability for a wide variety of therapeutic vaccines to improve efficacy, and convenience of use.Type: ApplicationFiled: November 4, 2005Publication date: April 6, 2006Inventors: Michel Cormier, James Matriano, Peter Daddona, Juanita Johnson, Wendy Young
-
Publication number: 20050106226Abstract: A drug delivery system for delivering a biologically active agent through the skin of a patient comprises (i) a pretreatment patch adapted to be placed on the patient's skin, the pretreatment patch having a backing membrane and a microprojection array, the microprojection array being adhered to the backing membrane, the microprojection array including a plurality of microprojections adapted to pierce the stratum corneum of the patient, the pretreatment patch including a skin template that remains on the patient's skin after the pretreatment patch is applied to and removed from the patient's skin, and (ii) a gel patch having a top and bottom surface, the gel patch including a reservoir containing a hydrogel formulation, the gel patch having a skin contact area in the range of approximately 0.5-30 cm2.Type: ApplicationFiled: October 21, 2004Publication date: May 19, 2005Inventors: Michel Cormier, WeiQi Lin, Juanita Johnson, Kofi Nyam
-
Publication number: 20050089554Abstract: An apparatus for transdermally delivering a biologically active agent comprising (i) a gel pack containing a hydrogel formulation and (ii) a microprojection member having top and bottom surfaces, a plurality of openings that extend through the microprojection member and a plurality of stratum corneum-piercing microprotrusions that project from said bottom surface of the microprojection member, the microprojection member being adapted to receive the gel pack whereby the hydrogel formulation flows through the microprojection member openings. Preferably, the hydrogel formulation comprises a water-based hydrogel.Type: ApplicationFiled: October 21, 2004Publication date: April 28, 2005Inventors: Michel Cormier, WeiQi Lin, Juanita Johnson, Kofi Nyam
-
Publication number: 20050025778Abstract: Microprojection members (10) having a reservoir containing an antigenic agent and methods of using such members to vaccinate mammals (e.g., humans) are disclosed. The microprojection members are used to transdermally deliver an antigenic agent (e.g., a vaccine antigen) with substantially reduced skin reactions. This is achieved by delivering an induction amount and thereafter delivering one or more subsequent booster amounts. The induction amount is relatively larger than the booster amount. This technology has broad applicability for a wide variety of therapeutic vaccines to improve efficacy and convenience of use.Type: ApplicationFiled: July 1, 2004Publication date: February 3, 2005Inventors: Michel Cormier, James Matriano, Juanita Johnson, Wendy Young, Peter Daddona
-
Publication number: 20040138610Abstract: A device and method are provided for percutaneous transdermal delivery of a biologically active agent by applying a microprojection array to the skin of a person or animal with a system that has a composite applicator tip and/or a composite microprojection array system.Type: ApplicationFiled: December 24, 2003Publication date: July 15, 2004Inventors: Michel Cormier, James Matriano, Juanita Johnson
-
Publication number: 20040062813Abstract: Methods are provided for preparation of a coating on one or more microprojections of a microprojection array using wetting agents either as a pretreatment of the microprojection surfaces or incorporated in the coating formulation along with the active agent.Type: ApplicationFiled: June 27, 2003Publication date: April 1, 2004Inventors: Michel J. N. Cormier, Wendy A. Young, Juanita A. Johnson, Peter E. Daddona, Mahmoud Ameri
-
Publication number: 20020193729Abstract: Skin patches (20) having a microprojection array (10), a reservoir (18) containing an antigenic agent and an immune response augmenting adjuvant, and methods of using same to vaccinate animals (e.g., humans) is disclosed. In a preferred embodiment, the microprojection arrays (10) are composed of a photoetched and micro-punched titanium foil (14). The microprojections (12) are coated with a liquid formulation containing a vaccine antigen and an adjuvant such as glucosaminyl muramyl dipeptide, dried, and applied to skin of the animal to be vaccinated using an impact applicator. The microprojections (12) create superficial pathways through the stratum corneum to facilitate permeation of antigenic agent and adjuvant. Antigen dose and depth of penetration can be controlled. This technology has broad applicability for a wide variety of therapeutic vaccines to improve efficacy, and convenience of use.Type: ApplicationFiled: April 20, 2002Publication date: December 19, 2002Inventors: Michel J.N. Cormier, James A. Matriano, Peter E. Daddona, Juanita A. Johnson, Wendy A. Young, Richard L. Keenan, Joseph C. Trautman
-
Publication number: 20020177839Abstract: The device including a plurality of stratum corneum-piercing microprojections, and a solid coating disposed upon the microprojections, wherein the solid coating includes at least one beneficial agent and a biocompatible carrier is provided. The device is applied to the skin of a living animal (e.g., a human), causing the microprojections to pierce the stratum corneum and deliver an effective dose of the agent to the animal.Type: ApplicationFiled: April 20, 2002Publication date: November 28, 2002Inventors: Michel J. N. Cormier, Wendy A. Young, Juanita A. Johnson, Peter E. Daddona
-
Publication number: 20020102292Abstract: This invention relates to a method for inhibiting a decrease in the transdermal flux of an agent that is being transdermally delivered or sampled over a prolonged period of time wherein the delivery or sampling involves disrupting at least the stratum corneum layer of the skin to form pathways through which the agent passes. The desired result is achieved by co-delivering or co-sampling the agent with an amount of at least one anti-healing agent wherein the amount of the anti-healing agent is effective in inhibiting a decrease in the agent transdermal flux compared to when the delivery or sampling of the agent is done under substantially identical conditions except in the absence of the anti-healing agent(s).Type: ApplicationFiled: September 8, 2001Publication date: August 1, 2002Inventors: Michel Cormier, Juanita Johnson, Wei Qi Lin, James Matriano, Peter Daddona
-
Patent number: 6203817Abstract: Transdermal compositions, devices, and methods for the administration of a drug at reduced skin irritation levels are disclosed. More particularly, this invention relates to novel methods, compositions, and devices for the reduction or elimination of irritation or sensitization caused by an irritating or sensitizing drug when it is delivered transdermally. According to a preferred embodiment, transdermal administration of a drug salt of a non-zwitterionic drug is disclosed wherein the drug salt comprises a combination of surface activity and a low octanol-water partition coefficient. Such drug salts have been found to reduce irritation or sensitization to the drug being delivered while achieving therapeutically effective transdermal fluxes.Type: GrantFiled: June 5, 1998Date of Patent: March 20, 2001Assignee: ALZA CorporationInventors: Michel J. N. Cormier, Peter E. Daddona, Juanita A. Johnson
-
Patent number: 5624415Abstract: An electrotransport delivery device utilizing reservoir buffering at a select pH ranges in order to reduce skin irritation and skin resistance is provided. Cathodic reservoirs are buffered to a pH of less than about 4, preferably to a pH in the range of about 2 to 4, while anodic reservoirs are buffered to a pH above about 4, preferably to a pH in the range of about 4 to 10. Another electrotransport delivery device utilizes a potassium sensor to monitor potassium efflux from the skin. Potassium efflux above a certain predetermined level has been found to be a precursor to skin irritation/erythema. Operation of the device is modified (eg, terminated) when the predetermined potassium efflux level is sensed.Type: GrantFiled: April 24, 1995Date of Patent: April 29, 1997Assignee: ALZA CorporationInventors: Michel J. N. Cormier, Philip W. Ledger, Juanita Johnson, Joseph B. Phipps, Stella Chao